2-(4-氟苯基)-1-(3-吡啶基)-乙酮 | 74767-71-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(4-氟苯基)-1-(3-吡啶基)-乙酮
• 英文名称: 4-fluorobenzyl 3-pyridyl ketone
• 英文别名: 2-(4-fluoro-phenyl)-1-pyridin-3-yl-ethanone；2-(4-Fluorophenyl)-1-(3-pyridinyl)-ethanone；2-(4-fluorophenyl)-1-pyridin-3-ylethanone
• CAS: 74767-71-8
• 化学式: C₁₃H₁₀FNO
• 分子量: 215.227
• InChiKey: YQIIFWFMYWXFQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-氟苯基)-1-(3-吡啶基)-乙酮 在 sodium ethanolate 、 sodium acetate 作用下， 以 四氢呋喃 、 乙醇 、 甲苯 为溶剂， 反应 8.5h， 生成 5-(4-fluorophenyl)-2-(4-methylsulfanylbenzylsulfanyl)-4-pyridin-3-ylpyrimidine
  参考文献：
  名称：

  From Imidazoles to Pyrimidines:  New Inhibitors of Cytokine Release

  摘要：

  On the basis of model imidazole inhibitors of cytokine release, a series of novel pyridinyl pyrimidine derivatives was prepared and tested on their ability to inhibit the release of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-beta) from peripheral blood mononuclear cells (PBMC) and human whole blood. In the pyrimidine series, structure-activity relationships (SARs) similar to those of the imidazole series were found, although generally pyrimidine compounds were less potent. Modification of the substituent at the 2 position of the pyrimidine led to the most active compound 14 which inhibited release of TNF-alpha (IC50 = 3.2 muM) and IL-1beta (IC50 = 2.3 muM) from PBMC as effectively as the model imidazole inhibitor ML 3163 (TNF-alpha, IC50 = 3.7 muM; IL-1beta, IC50 = 0-9 muM). Screening in an isolated enzyme assay revealed both imidazole and pyrimidine compounds as inhibitors of p38 MAP (mitogen-activated protein) kinase.

  DOI：

  10.1021/jm011098a

文献信息

• THERAPEUTIC FLUOROETHYL UREAS
  申请人：Chow Ken

  公开号：US20070270498A1

  公开（公告）日：2007-11-22

  Compounds of the formula or a pharmaceutically acceptable salt thereof or a tautomer thereof, wherein A and B are as described herein, are useful for treating conditions afflicting mammals.

  该公式化合物或其药用盐或其互变异构体，其中A和B如本文所述，可用于治疗影响哺乳动物的疾病。
• [EN] SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE<br/>[FR] PYRROLES DE PYRIDYLE SUBSTITUES, COMPOSITIONS CONTENANT DE TELS COMPOSES ET MODE D'UTILISATION
  申请人：MERCK & CO., INC.

  公开号：WO1997016442A1

  公开（公告）日：1997-05-09

  (EN) The present invention addresses substituted pyridyl pyrroles, as well as compositions containing such compounds and methods of treatment. The compounds in the present invention are glucagon antagonists and inhibitors of the biosynthesis and action of TNF-$g(a) and IL1. The compounds block the action of glucagon at its receptors and thereby decrease the levels of plasma glucose. The instant pyrroles are also inhibitors of TNF-$g(a) and IL1 and may be used as antidiabetic agents as well as other cytokine mediated diseases. Cytokine mediated diseases refer to diseases or conditions in which excessive or unregulated production of one or more cytokines occurs. Interleukin-1 (IL-1) and Tumor Necrosis Factor (TNF) are cytokines produced by a variety of cells, which are involved in immunoregulation and other physiological conditions, such as inflammation.(FR) La présente invention concerne des pyrroles de pyridyle substitués, des compositions contenant de tels composés et leur utilisation thérapeutique. Les composés de la présente invention sont des antagoniste du glucagon et des inhibiteurs de la biosynthèse et de l'action du facteur TNF-$g(a) et de l'IL1. Ces composés bloquent l'action du glucagon au niveau de ses récepteurs, ce qui diminue les niveaux de glucose du plasma. Les pyrroles de l'invention, qui sont également des inhibiteurs du facteur TNF-$g(a) et de l'IL1, peuvent servir d'antidiabétiques et contre d'autres affections à médiation des cytokines. L'interleukine-1 (IL-1) et le facteur de nécrose tumorale (TNF) sont des cytokines produites par diverses cellules qui interviennent au niveau de la régulation immunitaire et au niveau d'autres états physiologiques tels que les états inflammatoires.

  该发明涉及取代的吡啶基吡咯烷，以及包含这些化合物的组合物和治疗方法。本发明中的化合物是胰高血糖素拮抗剂和TNF-$g(a)和IL1的生物合成和作用的抑制剂。这些化合物阻止胰高血糖素在其受体上的作用，从而降低血浆葡萄糖水平。这些吡咯烷也是TNF-$g(a)和IL1的抑制剂，可以用作抗糖尿病剂以及其他细胞因子介导的疾病。细胞因子介导的疾病是指一种或多种细胞因子的过度或失控产生导致的疾病或病症。白细胞介素-1（IL-1）和肿瘤坏死因子（TNF）是由多种细胞产生的细胞因子，参与免疫调节和其他生理条件，如炎症。
• Antiinflammatory 4,5-diaryl-2-nitroimidazoles, method for their preparation and pharmaceutical composition containing them
  申请人：E.I. DU PONT DE NEMOURS AND COMPANY

  公开号：EP0008755B1

  公开（公告）日：1982-04-21
• US4199592A
  申请人：——

  公开号：US4199592A

  公开（公告）日：1980-04-22
• US4251535A
  申请人：——

  公开号：US4251535A

  公开（公告）日：1981-02-17